PODD
Insulet Beats on Every Q2 Metric Then Cuts the Outlook — Can the Type 2 Diabetes Bet Still Justify the Stock Price?
Shares of Insulet Corporation cratered 10.1% to $149.98 after the insulin-pump maker delivered a paradox: a strong quarter followed by a weaker road ahead....
